Personalis Announces Delivery of the 125,000th Genome
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 125,000th whole human genome...
Tag : genome technology
WhiteLab Genomics and the ART-TG Announce Their Collaboration
WhiteLab Genomics, specialist in artificial intelligence (AI) dedicated to gene and cell therapies, is entering into a collaboration with ART-TG, Inserm laboratory expert in the...
Gene Therapy Co. GenSight Biologics to Host a Webinar
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and...
Genomics-enabled Illumina To Webcast Upcoming Investor Conference
Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Healthcare Conference on June...
Genomic Diagnostics Company, Veracyte to Present at Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc...
Engine Biosciences Announces $43M Round to Decipher Genetic Codes
Important Findings from Pioneering Platform Advancing Drug Discovery and Development to Impact Treatments for Multiple Cancers Engine Biosciences (“Engine”) today announced the successful completion of an...
Moderna and Aldevron Expand Partnership for mRNA Vaccine
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and...
Genomic Medicine Company Sangamo Therapeutics Appoints New CFO
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial...
Brooklyn Strengthens Investment in mRNA Tech Platform with $20M
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating...
Gene-editing Co. Kiromic Submits FDA IND for a Clinical Trial
Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromic’s AI platform. Kiromic Biopharma, Inc. (Nasdaq: KRBP), an...